Tauklarify is a newly approved tau PET tracer that images tau tangles in the brain, while FDA-cleared Alzheimer's blood tests detect amyloid pathology. For memory clinic patients in 2026, blood tests usually start the amyloid workup and tau PET refines stage, prognosis, and treatment decisions.
Tau tangles are twisted tau protein deposits inside brain cells. Amyloid plaques are different protein deposits outside cells. The two test types answer different clinical questions.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does each test measure?
- Which blood tests are cleared for clinic use?
- Where does Tauklarify fit in 2026?
- What limits should patients plan for?
What does each test measure?
Amyloid blood tests check blood for signs of brain amyloid pathology. Amyloid PET also detects amyloid pathology. Tau PET visualizes neurofibrillary tangle pathology directly in the brain. The SNMMI-Alzheimer's Association workgroup explains that tau burden better reflects disease stage and future decline, as described in the workgroup summary.
A positive amyloid result says Alzheimer pathology is present. A tau PET result helps show how far that process has advanced. So the tests do not replace each other. A clinic can use amyloid testing to establish pathology and tau imaging to guide next choices.
Which blood tests are cleared for clinic use?
By fall 2026, four blood tests were cleared for amyloid-pathology assessment, each with different intended uses and cutoffs. They are not interchangeable.
Ask which exact test your clinic uses and what its cutoff means. The Alzheimer's Association guideline from July 29, 2025 applies to cognitively impaired patients in specialty memory care. It sets high accuracy bars for triage use and even higher bars to substitute for PET or spinal-fluid testing.
- Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio: first clearance, May 2025, to aid amyloid detection in symptomatic adults in specialty care. Fujirebio states it is not for screening or standalone diagnosis, according to the Fujirebio test information.
- Elecsys Phospho-Tau (217P) Plasma: single-biomarker p-tau217 test cleared to both rule in and rule out amyloid pathology in adults 55 and older with cognitive symptoms. AJMC reported the Aug. 24, 2026 clearance in the AJMC report.
- Elecsys pTau181 and PrecivityAD2: also cleared, with their own intended uses and cutoffs.
Where does Tauklarify fit in 2026?
Tauklarify, or florquinitau F18 from Lantheus and Cerveau, is the second FDA-approved tau PET tracer. Healio reported the Aug. 14, 2026 approval for brain PET in adults with cognitive impairment being evaluated for Alzheimer's to identify tau tangles in the Healio report. The first tau tracer, flortaucipir, was approved in 2020.
Tauklarify does not replace amyloid blood testing. It adds a newer imaging option when a doctor needs to see tau pathology. Updated Appropriate Use Criteria from SNMMI and the Alzheimer's Association, released in Jan. 2025, added formal tau-PET guidance. They recommend tau PET to refine eligibility, prognosis, and treatment decisions when amyloid status and clinical context are already known.
What limits should patients plan for?
Cleared blood tests require symptoms plus full medical, cognitive, and neurologic evaluation. They are not home screening tests. A normal clinic visit, memory testing, and medication review still come first.
About 1 in 5 Lumipulse results are indeterminate and need PET or spinal-fluid confirmation. Four Lumipulse reagent lots were also under FDA Class II recall for falsely elevated results. A repeat test or confirmatory PET can resolve an unclear answer.
- Bring a symptom timeline, medication list, and prior labs or brain scans.
- Ask whether your blood result is clearly positive, clearly negative, or indeterminate.
- Ask whether amyloid status, tau stage, or both will change treatment eligibility or trial referral.
- Confirm insurance coverage and where PET is done before you schedule.
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: What Memory Clinic Patients Should Know About the News
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: What Memory Clinic Patients Should Know About the News
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: What Is Established and What Remains Uncertain for Primary Care Patients
